ATEM Capital Fund LP

ATEM Capital (atemcap.com) is a NY-based Life Sciences investment fund that invests in breakthrough BioPharma / MedTech / Digital Health. Our prioritized therapeutic areas are platform technologies to cure oncology, autoimmune, cardiovascular, neurology diseases, and infections. In the last years, our team had over ten successful co-investments with the leading venture firms of the US and Europe: OrbiMed, Domain Associates, Canaan, ProQuest, LSP, Aisling Capital, MPM, Alta Partners, Frazier, Sofinnova, KPCB, as well as with the corporate venture firms: Pfizer, Roche, J&JDC, Novo, etc. Prioritized therapeutic areas are oncology, autoimmune diseases, rare diseases, and neurology. Our team members have extensive hands-on experience in product launches (over 40 products in the US and Europe), investments management (over $30 billion overall investment/liquidity), and exits of venture-backed companies.

ATEM Capital Fund LP, established in 2020 and headquartered in New York, New York, United States, North America., specializes in Seed, Early Stage Venture, Late Stage Venture investments across Artificial Intelligence (AI), Machine Learning, Life Science, Health Care, Bioinformatics, Biotechnology, Venture Capital, Oncology, Agriculture, Financial Services. The organization boasts a portfolio of 8 investments, with an average round size of $46.6M and 1 successful exits. Their recent investments include PGxCare, Walden Biosciences, Deka Biosciences, MPM Capital, Leaps by Bayer. The highest investment round they participated in was $58.9B. Among their most notable exits are PGxCare and Walden Biosciences. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.